- Home
- AKA vs VTVT Comparison
AKA vs VTVT Comparison
Compare AKA & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | VTVT |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 143.7M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AKA | VTVT |
|---|---|---|
| Price | $9.87 | $35.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $24.33 | ★ $55.25 |
| AVG Volume (30 Days) | 1.4K | ★ 29.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | $1,017,000.00 |
| Revenue This Year | $5.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $7.00 | $14.00 |
| 52 Week High | $16.90 | $44.00 |
Technical Indicators
Market Signals| Indicator | AKA | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 49.53 |
| Support Level | $9.31 | $33.62 |
| Resistance Level | $12.08 | $42.71 |
| Average True Range (ATR) | 0.28 | 3.17 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 20.51 | 29.90 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.